Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma
2024 · European Radiology · 2 citations
https://doi.org/10.1007/s00330-024-11191-8
E
Elias Mai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
22
Papers
10
Citations
2
h-index
0
i10-index
Elias Mai is an academic researcher from Heidelberg University. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Cancer Treatment and Pharmacology & Protein Degradation and Inhibitors. The author has an h-index of 2, co-authored 19 publications.
Papers by this author
worksAdditional file 1: of Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
2016 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.3623648_d1
Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03417-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat